CG
MDGL icon

Cutler Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cutler Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$763K Buy
32,000
+6,500
+25% +$1.53M 0.25% 94
2023
Q4 		$1.15M Sell
25,500
-7,700
-23% -$1.35M 0.1% 212
2023
Q3 		$2.6M Sell
33,200
-12,200
-27% -$2.3M 0.27% 78
2023
Q2 		$1.73M Buy
45,400
+32,500
+252% +$8.8M 0.24% 88
2023
Q1 		$360K Sell
12,900
-9,300
-42% -$2.53M 0.04% 448
2022
Q4 		$207K Buy
22,200
+19,000
+594% +$1.86M 0.02% 774
2022
Q3 		$68K Sell
3,200
-2,300
-42% -$160K ﹤0.01% 1670
2022
Q2 		$72K Sell
5,500
-500
-8% -$36.8K 0.01% 1672
2022
Q1 		$17K Buy
6,000
+4,800
+400% +$405K ﹤0.01% 3197
2021
Q4 		$4K Buy
1,200
+100
+9% +$8.22K ﹤0.01% 4358
2021
Q3 		$16K Buy
+1,100
New +$95K ﹤0.01% 3539
2021
Q1 		– Sell
-100
Closed -$1K – 6026
2020
Q4 		$1K Sell
100
-5,000
-98% -$611K ﹤0.01% 4475
2020
Q3 		$4K Buy
5,100
+2,400
+89% +$261K ﹤0.01% 3669
2020
Q2 		$4K Buy
2,700
+200
+8% +$19.7K ﹤0.01% 3473
2020
Q1 		$48K Sell
2,500
-200
-7% -$16.7K ﹤0.01% 1738
2019
Q4 		$42K Buy
2,700
+500
+23% +$48.5K ﹤0.01% 1741
2019
Q3 		$81K Sell
2,200
-6,800
-76% -$638K 0.01% 1195
2019
Q2 		$84K Buy
9,000
+4,600
+105% +$493K 0.01% 1195
2019
Q1 		$107K Buy
4,400
+1,800
+69% +$224K 0.01% 975
2018
Q4 		$138K Buy
2,600
+1,100
+73% +$170K 0.01% 844
2018
Q3 		$47K Buy
1,500
+900
+150% +$226K ﹤0.01% 1645
2018
Q2 		$4K Buy
+600
New +$105K ﹤0.01% 3242
2016
Q1 		– Sell
-100
Closed -$13K – 6883
2015
Q4 		$13K Buy
+100
New +$2.74K ﹤0.01% 3858

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cutler Group's MDGL Position: Q1 2024 in Review

Cutler Group increased its Madrigal Pharmaceuticals (MDGL) stake by 17% in Q1 2024, buying an estimated $542K and bringing the position to 15,800 shares worth $4.22M. The position accounts for 1.37% of the portfolio, ranked #6.

Cutler Group first reported a position in MDGL in Q4 2015 and has held it in 28 quarters since. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • Cutler Group held 15,800 shares of Madrigal Pharmaceuticals worth $4.22M as of Q1 2024.
  • Cutler Group bought 2,300 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $542K.
  • Madrigal Pharmaceuticals made up 1.37% of Cutler Group's portfolio in Q1 2024, its #6 holding.
  • Cutler Group first reported a position in Madrigal Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.